Stemedica Cell Technologies

San Diego, California-based biopharmaceutical company Stemedica Cell Technologies, Inc., manufactures and distributes high-quality allogeneic stem cells for use in world-class preclinical and clinical research. With one the largest stem cell production capacities in the world, Stemedica provides ischemic-tolerant stem cells to leading universities, research centers, and accredited medical facilities, which in turn utilize them to discover new biological medicines and treatments for various conditions. Licensed with the California Food and Drug Branch, Stemedica operates a facility approved by the U.S. Food and Drug Administration for its current good-manufacturing practices. This facility is supported by a second manufacturing facility in Lausanne, Switzerland which has proper Swissmedic approvals.

Since Stemedica’s founding in 2005, the company has supplied stem cells and related biologicals for research in four primary areas of medicine: neurology, cardiology, dermatology, and ophthalmology. Within each area, Stemedica supports research into medicines and treatments for specific diseases and conditions, such as stroke and Alzheimer's disease in neurology and macular degeneration and diabetic retinopathy in ophthalmology.

Stemedica effectively and efficiently manufactures its ischemic-tolerant products utilizing a number of patented, proprietary processes. These processes allow the business to produce large quantities of only the most viable stem cells. Stemedica also serves as one of the few stem cell providers to employ manufacturing technologies licensed for clinical trial application by regulatory agencies in several countries.

Stemedica currently has 18 patent applications on file in the United States and six patents in various stages of development. In December 2012, the company received U.S. patent approval for a multi-stem-cell treatment of several conditions causing adult blindness. The treatment focuses on diabetic retinopathy and diabetic optic neuropathy in particular. In the same month, the company announced a joint research investigation with the Scripps Research Institute into the use of Stemedica’s mesenchymal stem cells for the treatment of lung injury and sepsis.